Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.

IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
In vivo Pub Date : 2025-07-01 DOI:10.21873/invivo.14016
Yujiro Nagata, Takaomi Sugi, Sohei Yamamura, Yoshihiro Sugita, Yui Mizushima, Takuo Matsukawa, Tomohisa Takaba, Kazumasa Jojima, Katsuyoshi Higashijima, Masahiro Matsumoto, Akinori Minato, Ikko Tomisaki, Eiji Kashiwagi, Naohiro Fujimoto
{"title":"Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.","authors":"Yujiro Nagata, Takaomi Sugi, Sohei Yamamura, Yoshihiro Sugita, Yui Mizushima, Takuo Matsukawa, Tomohisa Takaba, Kazumasa Jojima, Katsuyoshi Higashijima, Masahiro Matsumoto, Akinori Minato, Ikko Tomisaki, Eiji Kashiwagi, Naohiro Fujimoto","doi":"10.21873/invivo.14016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Currently, there are no established predictive or prognostic biomarkers for first-line enzalutamide (ENZ) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). This multicenter study aimed to assess the predictive and prognostic significance of the initial-to-nadir prostate-specific antigen (PSA) ratio (I/N PSA) during primary androgen-deprivation therapy for <i>de novo</i> metastatic castration-sensitive prostate cancer in relation to the response to first-line ENZ in mCRPC.</p><p><strong>Patients and methods: </strong>A total of 33 patients with mCRPC receiving first-line enzalutamide were included in the study to investigate the correlation between I/N PSA in combined androgen blockade and clinical outcomes. Patients were dichotomized by median I/N PSA values. A PSA response was defined as a 90% or greater decline in PSA levels following the initiation of ENZ treatment in patients with mCRPC.</p><p><strong>Results: </strong>The median I/N PSA was 382. In the high I/N PSA (≥382) group, the PSA response rate was 75.0%, significantly higher than that in the low I/N PSA group (35.3%; <i>p</i>=0.037). The median overall survival following ENZ treatment was significantly better in the high I/N PSA group than in the low group (<i>p</i>≤0.01). Multivariable analysis demonstrated I/N PSA as an independent predictor of overall survival (hazard ratio=0.20; <i>p</i>≤0.01).</p><p><strong>Conclusion: </strong>In patients with mCRPC, the I/N PSA is a promising predictive and prognostic biomarker for first-line ENZ treatment and may provide personalized approaches in daily practice.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2209-2218"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aim: Currently, there are no established predictive or prognostic biomarkers for first-line enzalutamide (ENZ) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). This multicenter study aimed to assess the predictive and prognostic significance of the initial-to-nadir prostate-specific antigen (PSA) ratio (I/N PSA) during primary androgen-deprivation therapy for de novo metastatic castration-sensitive prostate cancer in relation to the response to first-line ENZ in mCRPC.

Patients and methods: A total of 33 patients with mCRPC receiving first-line enzalutamide were included in the study to investigate the correlation between I/N PSA in combined androgen blockade and clinical outcomes. Patients were dichotomized by median I/N PSA values. A PSA response was defined as a 90% or greater decline in PSA levels following the initiation of ENZ treatment in patients with mCRPC.

Results: The median I/N PSA was 382. In the high I/N PSA (≥382) group, the PSA response rate was 75.0%, significantly higher than that in the low I/N PSA group (35.3%; p=0.037). The median overall survival following ENZ treatment was significantly better in the high I/N PSA group than in the low group (p≤0.01). Multivariable analysis demonstrated I/N PSA as an independent predictor of overall survival (hazard ratio=0.20; p≤0.01).

Conclusion: In patients with mCRPC, the I/N PSA is a promising predictive and prognostic biomarker for first-line ENZ treatment and may provide personalized approaches in daily practice.

原发性雄激素剥夺治疗期间前列腺特异性抗原下降预测转移性去势抵抗前列腺癌患者接受恩杂鲁胺的反应和生存。
背景/目的:目前,对于转移性去势抵抗性前列腺癌(mCRPC)患者,恩杂鲁胺(ENZ)一线治疗还没有确定的预测或预后生物标志物。这项多中心研究旨在评估初始至最低点前列腺特异性抗原(PSA)比率(I/N PSA)在原发性雄激素剥夺治疗中对新转移性去势敏感前列腺癌的预测和预后意义,以及与mCRPC中一线ENZ反应的关系。患者和方法:本研究共纳入33例接受一线恩杂鲁胺治疗的mCRPC患者,探讨联合雄激素阻断I/N PSA与临床结局的相关性。根据I/N中位PSA值对患者进行二分类。PSA应答被定义为mCRPC患者在开始ENZ治疗后PSA水平下降90%或更高。结果:中位I/N PSA为382。高I/N PSA组(≥382)的PSA有效率为75.0%,显著高于低I/N PSA组(35.3%;p = 0.037)。高I/N PSA组ENZ治疗后的中位总生存期显著优于低I/N PSA组(p≤0.01)。多变量分析表明,I/N PSA是总生存率的独立预测因子(风险比=0.20;p≤0.01)。结论:在mCRPC患者中,I/N PSA是一线ENZ治疗的有希望的预测和预后生物标志物,并可能在日常实践中提供个性化的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
In vivo
In vivo 医学-医学:研究与实验
CiteScore
4.20
自引率
4.30%
发文量
330
审稿时长
3-8 weeks
期刊介绍: IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信